drugset
Drugs / pyrazoloacridine
last change Feb 2008 re-read 3 minutes ago

pyrazoloacridine

also known as PZA · NSC-366140 · NSC-627168 · PD 115934

Small molecule

Developed for
breast cancer · central nervous system neoplasm · cutaneous melanoma · liver cancer · lung cancer · metastatic malignant neoplasm · neuroblastoma · ocular melanoma
Investigated by
National Cancer Institute (NCI) · Barbara Ann Karmanos Cancer Institute · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · M.D. Anderson Cancer Center · Ohio State University Comprehensive Cancer Center

Trials 8

today NCT00053950 · Ph 1 NCT00005976 · Ph 2 NCT00006355 · Ph 1/2 NCT00003802 · Ph 2 NCT00003041 · Ph 2 NCT00002656 · Ph 2 NCT00002585 · Ph 2
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00053950 Dec 2002 → Mar 2007 neuroblastoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00006355 May 2000 → Oct 2004 central nervous system neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 26 trials
Phase 2 NCT00005976 May 2000 → Dec 2006 central nervous system neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00003802 Feb 1999 → Oct 2002 cutaneous melanoma, ocular melanoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 2 NCT00003041 Jul 1997 → Jan 2002 breast cancer Ohio State University Comprehensive Cancer Center Completed No outcome recorded
Phase 2 NCT00002656 Oct 1995 → Dec 2001 lung cancer Barbara Ann Karmanos Cancer Institute Completed No outcome recorded
Phase 2 NCT00002585 Feb 1994 → Oct 1999 breast cancer Barbara Ann Karmanos Cancer Institute Completed No outcome recorded
Phase 2 NCT00003714 — liver cancer, metastatic malignant neoplasm M.D. Anderson Cancer Center Withdrawn No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as pyrazoloacridine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00053950 ↗
7

NCT00006355 ↗

NCT00003714 ↗

NCT00002585 ↗

NCT00003802 ↗

NCT00005976 ↗

NCT00002656 ↗

NCT00003041 ↗
Known as NSC-366140 “A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma” NCT00003802 ↗
1

“Pyrazoloacridine, PZA, NSC-366140.” NCT00002656 ↗
Known as NSC-627168 ChEMBL registry synonym — accepted as the source's own label CHEMBL118841 ↗
Known as PD 115934 ChEMBL registry synonym — accepted as the source's own label CHEMBL118841 ↗
Known as PZA “Pyrazoloacridine (PZA), a rationally synthesized acridine derivative, has shown promising antitumor activity against glioma lines in combination with platinum compounds.” PMID 16133802 ↗ Oct 2005
4

“All patients receive intravenous pyrazoloacridine (PZA) every 3 weeks in the absence of progressive disease or unacceptable toxicity.” NCT00002585 ↗

“Patients receive pyrazoloacridine (PZA) IV over 3 hours on day 1.” NCT00006355 ↗

“Pyrazoloacridine, PZA, NSC-366140.” NCT00002656 ↗

“PZA” NCT00003714 ↗
Modality Small molecule “Pyrazoloacridine (PZA), a rationally synthesized acridine derivative” PMID 16133802 ↗ Oct 2005
Route Intravenous “All patients receive intravenous pyrazoloacridine (PZA) every 3 weeks in the absence of progressive disease or unacceptable toxicity.” NCT00002585 ↗